| |
|
|
 |
|
print
|
|
|
|
|
How It Works
Scientists at BioWa’s parent company, Kyowa Hakko Kirin., Ltd. (KHK), demonstrated that an antibody with a reduced fucose content in glycan moieties exhibited much higher antibody dependent cellular cytotoxicity (ADCC) activity compared to a normally fucosylated antibody. It was confi rmed that the mechanism behind the enhanced ADCC of a low-/no-fucose antibody was its increased affi nity to FcγRIIIa (CD16), the major Fc receptor for ADCC in humans.
To take advantage of this, a CHO cell line was created with the gene responsible for fucose addition (FUT-8) knocked out to create Potelligent® CHO. Potelligent® CHO produces fucose-free antibodies (Potelligent® mAbs) with enhanced ADCC activity. |
Mechanism of Potelligent® Technology with the FUT-8 gene knocked out to create fucose-free
antibody. |
To date, Potelligent® mAbs:
— Exhibit enhanced ADCC activity even with the low-ADCC allotype of CD16, overcoming CD16 polymorphism
— Exert potent cytotoxicity against low-density antigens
— Work efficiently in whole blood
— Retain desirable features of mAbs, such as Protein A binding
Several Potelligent® mAbs are currently in clinical trials. |
|
|
|
|
|
|
|
|
 |
;)
